Dihydrotestosterone regulates oxidative stress and immunosuppressive cytokines in a female BALB/c mouse model of Graves’ disease

References

• Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves' disease. Autoimmun Rev. 2014;13:398–402.
   PubMed Web of Science ®Google Scholar
• De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388:906–918.
   PubMed Web of Science ®Google Scholar
• Brent GA. Clinical practice. Graves' disease. N Engl J Med. 2008;358:2594–2605.
   PubMed Web of Science ®Google Scholar
• Schluter A, U, Flogel, S, Diaz-Cano, et al. Graves' orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model. Sci Rep. 2018;8:13096.
   PubMed Web of Science ®Google Scholar
• Kisiel B, Bednarczuk T, Kostrzewa G, et al. Polymorphism of the oestrogen receptor beta gene (ESR2) is associated with susceptibility to Graves' disease. Clin Endocrinol (Oxf). 2008;68:429–434.
   PubMed Web of Science ®Google Scholar
• Liu L, Wu L, Gao A, et al. The influence of dihydrotestosterone on the development of Graves' disease in female BALB/c mice. Thyroid. 2016;26:449–457.
   PubMed Web of Science ®Google Scholar
• Stummvoll GH, DiPaolo RJ, Huter EN, et al. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory t cells. J Immunol. 2008;181:1908–1916.
   PubMed Web of Science ®Google Scholar
• El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010;5:189–197.
   PubMed Web of Science ®Google Scholar
• Cools N, Ponsaerts P, Van Tendeloo VF, et al. Regulatory T cells and human disease. Clin Dev Immunol. 2007:2007;89195.
   PubMedGoogle Scholar
• Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569.
   PubMed Web of Science ®Google Scholar
• Kochetkova I, Golden S, Holderness K, et al. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 2010;184:7144–7153.
   PubMed Web of Science ®Google Scholar
• Mancini A, Di Segni C, Raimondo S, et al. Thyroid hormones, oxidative stress, and inflammation. Mediat Inflamm. 2016;2016:6757154.
   PubMed Web of Science ®Google Scholar
• Lassoued S, Mseddi M, Mnif F, et al. A comparative study of the oxidative profile in Graves' disease, Hashimoto's thyroiditis, and papillary thyroid cancer. Biol Trace Elem Res. 2010;138:107–115.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44–84.
   PubMed Web of Science ®Google Scholar
• Bednarek J, Wysocki H, Sowinski J. Oxidation products and antioxidant markers in plasma of patients with graves' disease and toxic multinodular goiter: effect of methimazole treatment. Free Radic Res. 2004;38:659–664.
   PubMed Web of Science ®Google Scholar
• Valea A, Georgescu CE. Selenoproteins in human body: focus on thyroid pathophysiology. Hormones (Athens). 2018;17:183–196.
   PubMedGoogle Scholar
• Jia J, Wu YH, Zhou XQ, et al. Effects of testosterone propionate on oxidative stress and the expression of spleen cytokine genes in endosulfan-treated mice. J Environ Pathol Toxicol Oncol. 2012;31:17–26.
   PubMed Web of Science ®Google Scholar
• Ahlbom E, Grandison L, Bonfoco E, et al. Androgen treatment of neonatal rats decreases susceptibility of cerebellar granule neurons to oxidative stress in vitro. Eur J Neurosci. 1999;11:1285–1291.
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Nakahara M, Abiru N. Animal models of Graves' disease and Graves' orbitopathy. Curr Opin Endocrinol Diabetes Obes. 2015;22:381–386.
   PubMed Web of Science ®Google Scholar
• Ungerer M, Faßbender J, Li Z, et al. Review of mouse models of graves' disease and orbitopathy-novel treatment by induction of tolerance. Clinic Rev Allerg Immunol. 2017;52:182–193.
   PubMed Web of Science ®Google Scholar
• McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves' hyperthyroidism from animal models. Endocr Rev. 2005;26:800–832.
   PubMed Web of Science ®Google Scholar
• Ye F, Hou P, Wu X, et al. The significance of immune-related molecule expression profiles in an animal model of Graves' disease. Autoimmunity. 2012;45:143–152.
   PubMed Web of Science ®Google Scholar
• von Engelhardt N, Carere C, Dijkstra C, et al. Sex-specific effects of yolk testosterone on survival, begging and growth of zebra finches. Proc Biol Sci. 2006;273:65–70.
   PubMed Web of Science ®Google Scholar
• Chen C-R, Pichurin P, Nagayama Y, et al. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest. 2003;111:1897–1904.
   PubMed Web of Science ®Google Scholar
• Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239:70–76.
   PubMed Web of Science ®Google Scholar
• Chen X, Du Y, Lin X, et al. CD4 + CD25+ regulatory T cells in tumor immunity. Int Immunopharmacol. 2016;34:244–249.
   PubMed Web of Science ®Google Scholar
• Jeon EJ, Yoon BY, Lim JY, et al. Adoptive transfer of all-trans-retinal-induced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model. Autoimmunity. 2012;45:460–469.
   PubMed Web of Science ®Google Scholar
• Zhu ML, P, Bakhru, B, Conley, et al. Sex bias in CNS autoimmune disease mediated by androgen control of autoimmune regulator. Nat Commun. 2016;7:11350.
   PubMed Web of Science ®Google Scholar
• Ansar Ahmed S, Young PR, Penhale WJ. Beneficial effect of testosterone in the treatment of chronic autoimmune thyroiditis in rats. J Immunol. 1986;136:143–147.
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis. Arch Neurol. 2007;64:683–688.
   PubMed Web of Science ®Google Scholar
• Gold SM, Chalifoux S, Giesser BS, et al. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflamm. 2008;5:32.
   PubMed Web of Science ®Google Scholar
• Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004;50:2858–2868.
   PubMed Web of Science ®Google Scholar
• Fijak M, Schneider E, Klug J, et al. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol. 2011;186:5162–5172.
   PubMed Web of Science ®Google Scholar
• Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol. 1997;159:3–6.
   PubMed Web of Science ®Google Scholar
• Marino M, Dottore GR, Leo M, et al. Mechanistic pathways of selenium in the treatment of Graves' disease and Graves' orbitopathy. Horm Metab Res. 2018;50:887–893.
   PubMed Web of Science ®Google Scholar
• Marino M, Menconi F, Rotondo Dottore G, et al. Selenium in Graves’ hyperthyroidism and orbitopathy. Ophthalmic Plast Reconstr Surg. 2018;34:S105–S110.
   PubMedGoogle Scholar
• Mseddi M, Ben Mansour R, Gargouri B, et al. Proteins oxidation and autoantibodies' reactivity against hydrogen peroxide and malondialdehyde-oxidized thyroid antigens in patients' plasmas with Graves' disease and Hashimoto Thyroiditis. Chem Biol Interact. 2017;272:145–152.
   PubMed Web of Science ®Google Scholar
• Kohrle J. Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes. 2013;20:441–448.
   PubMedGoogle Scholar
• Venditti P, Meo SD. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci. 2006;63:414–434.
   PubMed Web of Science ®Google Scholar
• Ademoğlu E, Ozbey N, Erbil Y, et al. Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease. Eur J Intern Med. 2006;17:545–550.
   PubMed Web of Science ®Google Scholar
• Rybus-Kalinowska BK, Zwirska-Korczala M, Kalinowski M, et al. [Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with non-autoimmunological subclinical hyperthyroidism]. Endokrynol Pol. 2009;60:199–202.
   PubMed Web of Science ®Google Scholar
• Aslan M, Cosar N, Celik H, et al. Evaluation of oxidative status in patients with hyperthyroidism. Endocrine. 2011;40:285–289.
   PubMed Web of Science ®Google Scholar
• Rybus-Kalinowska B, Zwirska-Korczala K, Kalinowski M, et al. Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with newly diagnosed Graves–Basedow disease and after thiamazole therapy leading to euthyroidism. Pol Arch Med. 2008;118:420–425.
   PubMedGoogle Scholar
• Tang XL, Liu XJ, Sun WM, et al. Oxidative stress in Graves' disease patients and antioxidant protection against lymphocytes DNA damage in vitro. Die Pharmazie. 2005;60:696–700.
   PubMed Web of Science ®Google Scholar
• Mayer L, Z, Romic, F, Skreb, et al. Antioxidants in patients with hyperthyroidism. Clin Chem Lab Med. 2004;42:154–158.
   PubMed Web of Science ®Google Scholar
• Abalovich M, Llesuy S, Gutierrez S, et al. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol. 2003;59:321–327.
   PubMed Web of Science ®Google Scholar
• Lee MN, Lee SH, Lee MY, et al. Effect of dihydrotestosterone on mouse embryonic stem cells exposed to H2O2-induced oxidative stress. J Vet Sci. 2008;9:247–256.
   PubMed Web of Science ®Google Scholar
• Giatti S, Rigolio R, Romano S, et al. Dihydrotestosterone as a protective agent in chronic experimental autoimmune encephalomyelitis. Neuroendocrinology. 2015;101:296–308.
   PubMed Web of Science ®Google Scholar
• Wu H, Li P, Shao N, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-beta in acute myeloid leukemia. Oncol Lett. 2012;3:1119–1123.
   PubMed Web of Science ®Google Scholar
• Zhou X, Kong N, Zou H, et al. Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity. 2011;44:43–50.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8:183–192.
   PubMed Web of Science ®Google Scholar
• Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507:366–370.
   PubMed Web of Science ®Google Scholar
• Stockis J, Colau D, Coulie PG, Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol. 2009;39:3315–3322.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Mohsenzadegan M. TGF-beta as a promising option in the treatment of multiple sclerosis. Neuropharmacology. 2009;56:929–936.
   PubMed Web of Science ®Google Scholar
• Essakalli M, Brick C, Bennani N, et al. [The latest TH17 lymphocyte in the family of T CD4+ lymphocytes]. Pathologie-biologie. 2010;58:437–443.
   PubMedGoogle Scholar
• Rocha EM, LA, Wickham, Z, Huang, et al. Presence and testosterone influence on the levels of anti- and pro-inflammatory cytokines in lacrimal tissues of a mouse model of Sjogren's syndrome. Adv Exp Med Biol. 1998;438:485–491.
   PubMed Web of Science ®Google Scholar
• McCarthy TL, Centrella M. Androgen receptor activation integrates complex transcriptional effects in osteoblasts, involving the growth factors TGF-beta and IGF-I, and transcription factor C/EBPdelta. Gene. 2015;573:129–140.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Han BM, Zhao FJ, et al. The differential effects of prostate stromal cells derived from different zones on prostate cancer epithelial cells under the action of sex hormones. Asian J Androl. 2011;13:798–805.
   PubMed Web of Science ®Google Scholar
• Wu L, Xun L, Yang J, et al. Induction of murine neonatal tolerance against Graves' disease using recombinant adenovirus expressing the TSH receptor A-subunit. Endocrinology. 2011;152:1165–1171.
   PubMed Web of Science ®Google Scholar
• Horie I, Abiru N, Saitoh O, et al. Distinct role of T helper Type 17 immune response for Graves' hyperthyroidism in mice with different genetic backgrounds. Autoimmunity. 2011;44:159–165.
   PubMed Web of Science ®Google Scholar